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ABSTRACT
The major drawback of melanoma therapy with BRAF and MAPK inhibitors is the 
innate and acquired drug resistance. We therefore explored alternative targets and 
developed a new compound, SAB298, that is a SRC-family kinase (SFK) inhibitor. The 
drug is cytotoxic to patient-derived melanoma cells regardless of oncogene expression 
and inhibits tumor growth in vivo. As expected, it inhibited SRC and PI3K activity, 
and had the additional property of ERBB2 inhibition, that lead to inactivation of the 
two ERK phosphatases PP2A and SHP2. In 57% of the melanoma cell lines tested, the 
consequent increase in ERK activity lead to proteolytic degradation of its substrate, 
the lineage specific transcription factor MITF, likely contributing to growth arrest. 
Treatment with a combination of SAB298 and AZD6244 (selumetinib), induced a 
synergistic growth inhibition, suggesting that the new compound could be used in 
the clinic as a substitute for, or in combination with MAPK inhibitors.
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INTRODUCTION
Current standard therapies for melanoma include 
treatments with checkpoint blockades or with vemurafenib 
and dabrafenib, small molecule inhibitors for BRAF and 
MEK. The combination therapy diminishes the activity of 
BRAFV600E/K present in 40–50% of melanomas [1, 2] and 
inhibits the mitogen-activated protein kinase (MAPK) 
pathway. However, there is an urgent need to identify new 
molecular pathways for targeting melanomas because 
of inherent or rapid emergence of resistance to MAPK 
inhibition [3–5]. In addition, melanomas that do not carry 
the BRAF oncogenes cannot be subjected to this type 
of therapy and are limited to treatments with immune 
checkpoint inhibitors, such as nivolumab, or combination of 
nivolumab with ipilimumab, approved by the FDA in 2016.
We sought to expand therapeutic possibilities 
using medicinal chemistry optimization strategies which 
led to the discovery of SAB298, a new kinase inhibitor 
that targets mostly members of the SRC-family kinase 
(SFK). SAB298 is an efficient inhibitor of a range of 
patient-derived melanoma cell lines, displaying a unique 
mechanism of action compared to other known SRC 
kinase inhibitors. 
RESULTS
SAB298 is the most cytotoxic SFK inhibitor to 
melanoma cells
SAB298 is a synthetic small molecule that has 
emerged from a rational design strategy for receptor and 
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non-receptor tyrosine kinases’ inhibitor. It contains the 
pyrazolo[3,4-d]pyrimidine core structure, has the (3S, 
4S) absolute configuration at the two stereogenic centers 
and features a substituted 1,2 dithiolane moiety that is 
unprecedented in kinase inhibitors (Figure 1). 
We first tested the impact of SAB298 on NCI-60 
human tumor cell lines that included eight melanomas 
(performed by the NCI Development Therapeutics 
Program). The results showed suppression of melanoma 
cell proliferation (IC50 of 21–550 nM), with the BRAF
V600E 
mutant melanoma cell line UCLA-SO-M14 (M14) being 
most sensitive (Supplementary Table 1). We therefore 
went on to screen the drug effect on a cohort of 30 patient-
derived short-term cultures of melanoma cell lines carrying 
BRAFV600E/K, NRASQ61K/L/R, NF1null, RAC1P129S, RAF1 or 
BRAF fusion proteins, as well as other mutations identified 
by exome-capture sequencing (Table 1 and Supplementary 
Table 2). Overall, the drug was particularly cytotoxic 
to cell lines that did not carry oncogenic mutations in 
BRAF or NRAS (double-WT), displaying a range of IC50 
between 81–717 nM (Median = 257 nM). Melanomas with 
BRAFV600E/K sub-grouped into lines that were sensitive (IC50 
55–282, Median =141 nM) or resistant (IC50 500–2,477 nM, 
Median = 697 nM), while the NRASQ61K/L/R mutants required 
relatively high concentrations of SAB298 to induce growth 
arrest (IC50 371–3,080 nM, Median = 752 nM) (Figure 2A, 
2B and 2C, summarized in 2D–2F). Interestingly, normal 
human melanocytes grouped with the resistant subtype (IC50 
968 nM, Figure 2A, orange). The cytotoxicity of SAB298 
was well demonstrated by the high values of AUC (Area 
Under the Curve) below the zero line for double wild-type 
melanoma cell lines (Figure 2F). Three-way Kruskal-Wallis 
analysis of the dot-plot display (Figure 2D) showed that the 
difference in the levels of response to SAB298 between 
the double-WT and NRAS-mutant melanoma cells were 
statistically significant, p-value = 0.002985.
SAB298 (0.5 µM and 1 µM) induced apoptosis 
as measured by annexin staining and caspase activity 
(Supplementary Figure 1A–1C). 
Comparing the potency of SAB298 to clinically-
relevant SFK-inhibitors showed that dasatinib, bosutinib, 
saracatinib, SU6656 and imatinib (the latter targeting 
ABL, KIT and PDGFR), had very little or no inhibitory 
effect (IC50 ~10,000 nM, Supplementary Figure 2A). On 
the other hand, UM-164, a modified dasatinib that binds 
to the inactive conformation of SRC kinase Asp-Phe-
Gly motif (DFG-out) and inhibits also p38 kinase [6], 
was effective independent of oncogenic mutations (IC50 
50–3,000 nM) (Supplementary Figure 2B–2E). However, 
compared to SAB298, UM-164 was less effective inhibitor 
for ~50% of the melanoma cell lines as indicated by the 
IC50 plots (Figure 2G), and less cytotoxic, as shown by the 
low levels of AUC1 scores (Figure 2H, compare empty 
to solid dots, and supplementary Figure 2E). We also 
confirmed the anti-melanoma activity of SAB298 in vivo. 
Daily administration (20 mg/kg), significantly suppressed 
the growth of established YUSIK melanoma tumors, 
compared to placebo control (p = 0.0006) (Figure 2I).
SAB298 suppressed cell proliferation as effectively 
as the ERK and MEK inhibitors (SCH772984 and 
AZD6244, respectively), which displayed wide range of 
activity when tested on our cohort of melanoma cells (IC50 
12->10,000 nM) [7]. In addition, SAB298 had synergistic 
inhibitory effect when combined with the MEK inhibitor 
AZD6244. The combination treatment dropped the IC50 
values to <10 nM, 127 nM and 43 nM in the BRAFV600E 
mutants YUSIK, 501 mel cells and the HRASQ61K mutant 
YUROB cells, respectively (Figure 3). The combination 
treatment had statistically strong synergism assuming 
mutually exclusive and nonexclusive mode of action of 
AZD6244 and SAB298 across all three cell lines. The 
Combination Index (CI) values were between 0.1 and 
0.3 based on the median-effect equation derived from the 
mass-action law principle [8, 9] to quantify synergism (see 
Supplementary Methods for details).
Altogether, the results show that SAB298 is an 
effective inhibitor of melanoma cell proliferation and can 
be used for targeted therapy in melanoma.
Figure 1: Structure of SAB298. The compound contains the pyrazolo[3,4-d]pyrimidine core structure, has the (3S, 4S) absolute 
configuration at the two stereogenic centers and features a substituted 1,2 dithiolane moiety that is unprecedented amongst kinase inhibitors. 
Its chemical name is (3S, 4S)-3-((4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-1,2-dithiolan-4-ol. 
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SAB298 inhibits SRC-family kinases, ERBB2 
and PIK3R 
We performed radioisotope filtration binding assay 
[10] that showed high affinity of SAB298 to several SRC-
family kinases (SFK), such as YES1, BLK, LCK, FGR, 
HCK and FYN (IC50 ranging from 0.7–21.7 nM), but very 
little to BRAF, RAF1, ARAF, ABL1, ABL2, WEE1 and 
ERBB2 (IC50 1,200->10,000 nM), or to IGF1R and CDK4/
cyclin D1 (IC50 >10,000 nM) (Supplementary Table 3). 
Furthermore, we applied the in situ KiNativ® screening 
test that confirmed the kinase selectivity of SAB298 
against several SFKs (IC50 <10–60 nM) including SRC, 
YES1, LYN, and CSK, and against ABL2, and the receptor 
kinases ERBB2 and ERBB3, with some variability 
between the two cell lines tested (YUSIV and YUSIK, 
Table 2). The ~10-fold and ~20-fold higher binding affinity 
of SAB298 to SRC and ERBB2 in the in situ KiNativ® 
assay compared to the radioisotope filtration binding assay 
done on purified compounds indicated stronger activity 
with the native conformation in the cellular milieu. There 
was very little activity against mTOR, EGFR, LCK and 
MEK1 (IC50 1,300–2,900 nM, Table 2). 
We confirmed that SAB298 inhibits SFK by 
probing with anti-IEDNEpYTAR antibodies for auto-
phosphorylated Y416 (pY416). Melanoma cell lines 
displayed variable levels of basal pY416, which was 
consistently suppressed by SAB298 (Figure 4, pY416 
SFK). In addition, SAB298 suppressed PI3K, the SRC 
downstream signaling target [11] observed by decrease 
in phospho-Y467/199 PIK3R1/3 (Figure 4, pY467/199 
PIK3R1/3). Interestingly, there was a correlation between 
the levels of pY416 SFK and pY467/199 PIK3R; cells 
that had very low or undetectable levels of pY416 SFK 
also displayed low or undetectable levels of pY467/199 
PIK3R (Figure 4, YUSEEP, YUSIK and YUKIM). 
However, the basal levels of pY416 SFK or pY467/199 
PIK3R were not markers for the sensitivity to the 
compound (Figure 4, compare the highly resistant 501 
mel, YUGASP and YUROB to the sensitive YUSIV, 
YUSIK and YUSEEP, IC50 and AUC shown on the 
bottom of each lane). In addition, the cell lines expressed 
different levels of SFK members, SRC, LYN, FYN and 
YES (Figure 4, as indicated), that may have a role in drug 
response.
We performed short hairpin RNA (shRNA) 
knockdown of SRC, LYN, YES, and FYN to identify the 
“addictive” SFK (Figure 5). The results show that SRC 
depletion in YUSIV, YUSIK and YUGASP melanoma 
cells induced growth arrest whereas 501 mel cells were 
not affected (Figure 5A). YUSIV melanoma cell line, the 
most sensitive to inhibition by SAB298, required LYN 
for optimal cell proliferation (Figure 5B), whereas there 
was only at most 50% reduction in growth in response to 
downregulation of YES and FYN (Figure 5B, 5C). Here 
again, the most resistant were 501 mel melanoma cells 
(Figure 5D).
SAB298 stimulates rather than inhibits MAPK 
signaling 
Time-course analysis revealed that treatment with 
SAB298 increased, rather than decreased, the levels of 
phospho-MEK S217/221 and phospho-ERK S217/221 
(pERK T202/Y204). This effect was observed within 
2–6 hours and was maintained throughout the 72 hours 
incubation with the inhibitor (Figure 6A). This unexpected 
long term signaling response was observed in YUSIV that 
carries PDE8A-RAF1 fusion protein and in BRAFV600E 
mutant melanomas (501 mel and SK-MEL-28). A similar 
response was observed in seven additional melanoma 
cell lines regardless of the presence or absence of BRAF 
or NRAS oncogenic mutations (Figure 6B). In all cases, 
there was either an increase in pERK Thr202/Tyr204 or no 
Table 1: Melanoma cell lines
Melanoma type Number of specimens
Sun-exposed 17
Acral 5
Ocular 2
Mucosal 1
Unknown 5
Total 30
BRAF/RAS Mutations* Number of Specimens
WT/WT 10
BRAFV600E/K/M 10
NRAS/HRASQ61K/R,G12D 9
BRAFG469A 1
*See Supplementary Table 2 for more information regarding the presence of other cancer genes.
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effect, especially when the levels of basal pERK Thr202/
Tyr204 were high (Figure 6B and Figure 7A). RAF activity 
was required to maintain pERK because the RAF1-dimer 
inhibitor BGB-283 abolished pERK (Figure 6C).
We examined if the “paradoxical” activation of the 
MAPK pathway is a common response to SRC inhibition 
in these melanoma cells. Side-by-side comparison of 
SAB298 and UM-164 confirmed that the two inhibitors 
downregulated pSFK Y416, but had an opposite effect 
on pERK T202/Y204 (Figure 7A). Additionally, in 
contrast to UM-164, SAB298 induced p38 T180/Y182 
phosphorylation within two hours, in a manner similar 
to that of pERK T202/Y204 stimulation (compare Figure 
7B to Figure 6A), but this effect subsided after ~24 hrs 
(Figure 7B). The results were not due to aberrant p38 
response in these melanoma cells, because the MEK1/2 
inhibitor trametinib effectively abolished pp38 T180/
Y182 (Figure 7C). The p38 kinase inhibitors ralimetinib 
and LY2228820 had little effect on melanoma cells 
(IC50 >10,000 nM data not shown), suggesting that this 
kinase does not carry a critical role in melanoma cell 
proliferation as it does for triple-negative breast cancer 
cells [6]. Altogether, we show that the SFK-inhibitor 
SAB298 is a potent suppressor of melanoma cell 
proliferation independent of pERK activity.
SAB298 inactivates MAPK phosphatases via 
inhibition of ERBB2 
The SAB298 induced MAPK activation was not 
the direct effect of SFK inhibition because it was not 
observed in response to knockdown of SRC, YES or FYN 
Figure 2: Suppression of cell proliferation in response to SAB298 and UM-164. The results show CellTiter-Glo® Luminescent 
Viability Assay and the values are average of triplicate or quadruplet wells, displayed as percent of control assessed at the end of 72 hours 
treatment ± SE. (A–C) Growth arrest in response to SAB298. The legends on the right provides the IC50, i.e., drug concentrations that 
reduced cell viability to 50% of the control generated in GraphPad Prism. Black, blue and red lines indicate melanoma cells that are wild-
type for BRAF or NRAS (double-wild type), BRAFV600E/K, or NRAS/HRASQ61 mutants, respectively. Green lines indicate ocular melanoma 
cells with GNA11Q209L, broken lines are NF1null (---), broken dot broken line are RAC1
P29S/NF1null double mutant (-.-), and orange line 
indicates normal human melanocytes that are wild type for all mutations. STDV was about 5% of total count. (D–F) show aligned dot-plot 
of SAB298 IC50 values, bar graph of increasing levels of IC50 and AUC (Area Under the Curve). Color code as in (A–C). Grey bars indicate 
melanoma with fusion genes and (H), indicates HRASQ61K mutation. (G and H) show comparisons between SAB298 ( ) and UM-164  
in IC50, AUC1. (I) Tumor growth in response to SAB298. YUSIK tumor bearing mice were treated daily with intraperitoneal injection of 
20 mg/kg SAB298 (red) starting on day 12 after injection or with solvent as control (blue). Data are average of 6 mice ± SEM. The p-value 
of 0.0006 was calculated by Uncorrected Fisher’s LSD using GraphPad based on the last day data.  NBMEL;  NF1;  NF1 and 
RAC1;  GNA11Q209L;  NRASG12D;  BRAFG469A.
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(Supplementary Figure 3). We therefore explored the role 
of two MAPK phosphatases, PP2A (encoded by PPP2CA) 
and SHP2 (encoded by PTPN11) [12–14]. Probing with 
antibodies to the inactivated PP2A (phospho-PP2A 
Y307) [15], showed increase in the levels of inactivated 
PP2A levels in response to SAB298, in a way similar to 
that of okadaic acid, a potent inhibitor of these protein 
phosphatases (Figure 8A, pPP2A Y307). In addition, 
SAB298 inactivated phospho-SHP2 Y542 in YUSIK, 
YUROB and YUSOC melanoma cell lines, but not in 
YUGASP (Figure 8B, 8C). The general levels of pSHP2 
Y542 was inversely proportional to the levels of pERK 
(compare Figure 8 to Figure 6B). 
Because SHP2 activity is modulated by receptor 
tyrosine kinases [16], we tested if ERBB2 inhibition, 
an additional in situ target of SAB298 (Table 2), is the 
cause of this process. The results confirmed that SAB298 
suppressed phospho-ERBB2 Y1196 (Figure 8C and 8D, 
YUSOC, YUROB, YUSIV, YUTOGS). Interestingly, 
YUROB melanoma displayed extremely high levels 
of pERBB2 Y1196 that was abolished by SAB298 
(Figure 8D). We concluded that pERK activation is the 
consequence of reduced PP2A and SHP2 activities, due 
to ERBB2 inhibition by SAB298. However, inhibition 
of ERBB2 with the potent ERBB2/ERBB3 inhibitor 
sapitinib, or with anti-ERBB3 antibody MM121, had very 
little effect on cell proliferation (YUSIV and YUSIK, IC50 
>10,000 nM), while the EGFR/ ERBB2/ ERBB4 inhibitor 
dacomitinib had somewhat better inhibitory effect (IC50 
1,200 nM and 2,600 nM, respectively), suggesting that 
ERBB2 is not directly involved in SAB298 induced 
growth arrest.
SAB298 downregulates MITF
We examined the long-term effects of SAB298, such 
as the expression of cyclin D1, MYC, p27CIP, and p53, 
but did not observe any consistent shared response (data 
not shown). On the other hand, we checked the impact 
of ERK activation on MITF (melanogenesis associated 
transcription factor) because MITF is a critical transcription 
factor for melanocyte and melanoma cell proliferation 
[17], whose stability is reduced when phosphorylated by 
MAPK or KIT [18, 19]. The results showed that SAB298 
suppressed MITF levels in four out of seven melanoma 
cell lines (YUSIV, YUSIK, SK-MEL-28 and YUKIM), but 
not in YUPEET, YUSEEP and 501 mel cells (Figure 9A). 
However, there was no correlation between IC50 levels and 
MITF downregulation (Figure 9A, indicated on the bottom 
for each cell line), suggesting that melanoma cells differ in 
their dependence on MITF. 
The ERK-inhibitor SCH772984 validated the 
role of the kinase activity in downregulating MITF. 
Incubation with SCH772984 increased the basal levels 
of the transcription factor in YUSIV and abolished 
its downregulation by SAB298 in both YUSIV and 
YUSIK melanoma cells (Figure 9B). Furthermore, the 
addition of the proteasome inhibitor MG-132 (20 µM 
for 24 hrs) abolished SAB298 impact on MITF (Figure 
9C), in agreement with published reports showing that 
the phosphorylated transcription factor is a target to 
proteasome degradation [18, 19]. In contrast to SAB298, 
UM-164 increased MITF levels (Figure 9D) as a 
consequence of ERK inhibition (Figure 7A). 
We tested if modulation of MITF had a physiological 
effect as it can impact the expression of melanocyte-
specific genes, such as tyrosinase. We show that indeed, 
SAB298 suppressed the levels of tyrosinase in melanoma 
cells that express the protein (Figure 9E, YUSIK, YUKIM 
and YUPEET), suggesting that downregulation of this 
transcription factor can contribute to SAB298 inhibition 
of cell proliferation in some cell lines.
DISCUSSION
Targeting SRC in melanoma has been of interest for 
over a decade [20]. Published results with three melanoma 
cell lines showed that dasatinib and bosutinib had a minor 
Figure 3. Synergistic Inhibition of BRAFV600E Melanoma Cell Proliferation by Treatment with SFK and MEK Inhibitors. Cell 
proliferation of YUSIK, 501 mel and YUROB melanoma cell lines (A, B and C, respectively) in response to SAB298 (blue), AZD6244 
(red), and AZD6244 plus SAB298 (green). SAB298 was added to AZD6244 at 0.15 µM (YUSIK), or 0.4 µM (501 mel and YUROB). The 
IC50 for each drug alone and in combination are indicated in the legend for each cell line. 
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impact (IC50 1,300–10,000 nM) [20], and in another case, 
dasatinib did not have an effect on cell proliferation, but 
inhibited migration and invasion [21]. Additional studies 
showed that SRC-I1 (SRC inhibitor-1) was inactive 
on patient-derived BRAFV600E mutant melanoma cells 
resistant to vemurafenib, but enhanced the activity of 
the pan-RAF inhibitor TAK632 against these cells [22]. 
Furthermore, phase 2 clinical trials with dasatinib and 
saracatinib had minimal clinical activity as a single agent 
in patients with advanced melanoma [23], and response 
rate to dasatinib among melanoma patients with KIT 
activating mutation was low [24]. This is in contrast to 
the highly efficient effect of dasatinib in BCR-ABL-
driven diseases such as chronic myeloid leukemia (CML) 
and Philadelphia-chromosome-positive acute 
lymphoblastic leukemia (Ph+ ALL), characterized by the 
constitutively active tyrosine kinase, BCR-ABL [25].
We described a new compound, SAB298, that 
binds to the ATP kinase domain of several SFKs, and 
inhibits melanoma cell proliferation in vitro and in vivo, 
and affects other cancer cell types as well (lymphoblastic 
leukemia, carcinoma, astrocytoma) regardless of oncogene 
expression. The compound has multiple targets, the 
SFK family members and ERBB2/3, but has very little 
activity against BRAF, RAF1, ARAF, IGF1R or CDK4/
Cyclin D1. It is common for kinase inhibitors to target 
more than one protein. For example, dasatinib inhibits 
SRC, c-Kit, ephrin receptors and BCR/Abl; imatinib 
targets ABL, KIT and PDGFR; SU6656 targets SRC 
family kinases and BRSK2, AMPK, Aurora C, Aurora B, 
CaMKKβ; and bosutinib and saracatinib inhibit SRC and 
ABL kinases. Quantitative analysis of 178 commercially 
available kinase inhibitors against a panel of 300 
recombinant protein kinases revealed a wide spectrum 
of promiscuity and identified multitargeted inhibitors of 
specific, diverse kinases [26], indicating that SAB298 is 
not more promiscuous compared to other kinase inhibitors.
Our studies included 30 different patient-derived 
melanoma cell lines well characterized for mutations 
and genomic aberrations. Although double-wild type 
(BRAF/NRAS) melanoma cells were the most sensitive 
to the compound (with IC50 below 400 nM), the BRAF
V600 
mutant cells included a group of highly responsive and 
less responsive melanoma cells (IC50 below 400 nM 
and above 500 nM, respectively). Melanoma cells with 
oncogenic NRAS were the least sensitive (IC50 above 400 
nM). On the other hand, alterations in NF1, including early 
termination, were not sufficient to raise the resistance of 
double-wild cells, such as YUSOC (IC50 157), YUHEF 
(IC50 257, NF1 pQ853X) and YUTOGS (IC50 347, NF1 
p.W336X/E337K), or cells carrying the fusion protein 
PDE8A-RAF1 YUSIV (IC50 81 nM, NF1 p.L626F), 
but may had an impact on one BRAFV600K/M melanoma 
(YUCHIME) displaying extreme resistance (IC50 2,477 
nM, NF1 p.K1714N). There was high correlation between 
the levels of pSFK and pPIK3R1/3, but the variability 
between the cellular responses did not correlate with 
the phosphorylated levels of these markers, and pSFK 
intensity levels did not correlate with the presence 
or absence of a melanoma oncogene. Interestingly, 
knockdown expression revealed that melanoma cells 
sensitive to the compound are “addicted” to SRC and LYN 
activity. 
We explored the long term effects of SAB298. 
The substance induced caspase activity and apoptosis, 
regardless of p53, MYC, p27KIP and cyclin D1 expression 
(data not shown). On the other hand, we identified in about 
57% of the cell lines, a potent and unique SAB298 function 
of downregulating MITF, a lineage-transcription factor 
for melanocytes and melanomas. We demonstrated that 
Table 2: KiNativ™ assay tests for SAB298 target protein*
Kinase YUSIV YUSIK
YES1 <10 Not Present
SRC 31 Not Present
LYN 60 190
ABL2 87 240
ERBB3 290 240
MEK5 370 1500
CSK 420 910
ERBB2 410 530
mTOR 1,300 2,000
EGFR 1,300 530
LCK 1,400 Not Present
RIPK2 Not Present 20
MEK1 2,900 Not Present
*The results show IC50 in nM. Values were determined from 3-point dose response curve.
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downregulation of MITF is the consequence of a known 
pathway, in which MAPK activation phosphorylates the 
transcription factor and targets it to degradation [27]. In 
contrast, UM-164 inhibited ERK and caused activation 
of MITF, an effect that may reduce the long term impact 
on cell proliferation and contribute to the development 
of drug resistance as described for BRAF- and MEK 
inhibitors [28]. Analysis of biopsies from BRAFV600E 
melanoma patients following relapse with vemurafenib, 
or combination of dabrafenib and trametinib revealed 
upregulation of several lineage-specific transcription 
factors including MITF [29]. The increased levels of 
MITF in response to inhibition of MAPK was observed 
within the first two weeks of treatment [30]. Furthermore, 
the melanoma cells from tumor-bearing mice treated with 
vemurafenib were more tolerant to BRAF inhibition than 
cells isolated from untreated tumors [30], and the protease 
inhibitor nelfinavir mesylate suppressed MITF expression 
and sensitizes BRAF and NRAS mutant melanoma to 
MAPK inhibitor treatment. In another study, in vitro and 
in vivo studies with the CH6868398, demonstrated that 
reduction of MITF levels increased the response to the 
BRAF inhibitor PLX4720 [31]. Altogether, our data show 
that one possible cause for resistance to SRC-inhibitors is 
Figure 4: SAB298 suppresses SFK and PI3K activities. Western blot analyses of melanoma cells treated with DMSO or 
SAB298 (0.5 µM) for 5 hrs. Cell extracts were probed with antibodies to phosphorylated SFKs (SFK pY416), phosphorylated PI3KR1/3 
(pY467/199), to different SFKs or PIK3R as indicated. Reduction in the levels of pSFK Y416 in response to SAB298 indicates inhibition 
of SFK. Two cell lines (SK-MEL-28 and YUSEEP) did not express detectable levels of SFK pY416. Anti-actin represents protein loading. 
The levels of growth responses to SAB298 are indicated by the IC50, AUC1 and AUC2 on the bottom of each lane. YUSIV and YUSEEP 
carry PDE8A-RAF1 or GOLGA4-RAF1 fusion proteins, respectively.
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Figure 5: Cell proliferation in response to downregulation of specific SFKs. The histograms show cell proliferation of 
melanoma cells infected with shRNA targeting SRC, LYN, YES or FYN compared to none-infected cells (None) and control shRNA 
(Control) (left panels A–D). The shRNA knockdown was validated by western probing for the expression of the SFK employing the 
respective antibodies (right panels A–D). SFK: SRC Family Kinase. 
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the increase in MITF, a problem that is not reproduced by 
SAB298 (summarized in Figure 10).
MATERIALS AND METHODS
SAB298 and other SRC-kinase inhibitors
SAB298 was synthesized in six steps according 
to the procedures outlined in WO 2018/049127 patent 
application (examples 3, 15, 17, 44, 45 and 46). Its activity 
was compared to UM-164 (Sigma-Aldrich, St. Louis, 
MO), dasatinib (BMS 354825), bosutinib (SKI-606), 
saracatinib, SU6656, sapitinib (AZD8931), ralimetinib 
(LY2228820), dacomitinib, lifirafenib (BGB-283) and 
SCH772984 (all from Selleckchem, Houston, TX), 
okadaic acid (MilliporeSigma, St. Louis, MO), trametinib 
(LC Laboratories, Woburn), and imatinib (NCI).
Growth responses and apoptosis
SFK-inhibitors were tested on a panel of NCI-60 cell 
lines (Supplementary Table 1) and 30 melanoma cell lines 
and NBMEL, i.e., normal human melanocytes isolated 
from a newborn foreskin (Table 1 and Supplementary Table 
2). The Yale melanoma cohort designated YU originated 
from tumors excised to improve patient quality of life 
and used with participants’ informed consent according 
to Health Insurance Portability and Accountability Act 
(HIPAA) regulations with Human Investigative Committee 
protocol. 
The melanoma cells were grown in OptiMEM 
(Invitrogen, Carlsbad, CA) supplemented with 5% fetal 
calf serum and antibiotics. The normal human melanocytes 
(NBMEL) were grown in medium supplemented with 
bFGF, IBMX and dbcAMP [32]. Most of the Yale 
melanoma cell lines were characterized by next-generation 
sequencing [7, 33] (Supplementary Table 2).
Cell proliferation was measured with the CellTiter-
Glo® Luminescent Cell Viability Assay (Promega 
Corporation, Madison, WI). Melanoma cells were 
seeded in 96-well plates in triplicate or quadruplet wells, 
with increasing concentrations of kinase inhibitors for 
72 hrs. The rate of proliferation was also tested after 
knockdown of different SRC-family kinases (SFK) with 
hairpin lentivirus shRNA as indicated. The IC50 (the dose 
that elicits 50% inhibition compared to vehicle control) 
Figure 6: MAPK signaling is activated in response to SAB298. Melanoma cells were treated with SAB298 (0.5 µM or 1 µM, as 
indicated) and harvested at increasing time points (A), or after 5-6 hours (B, C). The panels show western blots probed with antibodies to 
phosph-ERK1/2 Thr202/Tyr204 mAb (pERK), ERK1/2 (ERK), phospho-MEK1/2 (pMEK), and actin as protein loading control. (C) Cells 
were treated with SAB298, BGB-283 (a RAF-dimer inhibitor), or both for 6 hrs to validate the role of RAF kinase in ERK phosphorylation. 
The mutation status of each cell line is indicated on the top.
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and AUC (area under the curve) were calculated from 
the slope of the drug response by linear interpolation 
employing GraphPad Prism 7 software [32]. The statistical 
significance of synergism of response to drug combinations 
was evaluated by following Chou and Talalay algorithm [8, 
9]. See also details in Supplementary Material.
The rate of apoptosis was measured using 
the Dead Cell Apoptosis Kit with Alexa Fluor® 488 
annexin V and propidium iodide (Invitrogen, V13241). 
Phosphatidylserine was visualized by flow cytometry 
following the manufacturer’s instructions. The assay was 
done in response to SAB298 (0.5 µM and 1 µM, 24 hrs), 
compared to DMSO (negative control) or camptothecin 
(10 µM), as a positive control. In addition, we used the 96-
well colorimetric Caspase 3 Assay kit (Millipore Sigma) 
to measure caspase activity in response to increasing 
concentrations of SAB298, and western blotting for 
apoptotic markers, such as cleaved PARP. 
Screening of SAB298 cellular targets 
The effect of SAB298 on a panel of 36 recombinant 
kinases, was screed with the radioisotope filter binding 
assay [10, 26] employing 10 concentrations of the 
compound with 10 µM ATP (Reaction Biology Corporation, 
Malvern, PA). In addition, we tested the endogenous 
kinome response to SAB298 (0.05 µM, 0.5 µM and 5 
µM) in lysates from two melanoma cell lines (YUSIV and 
YUSIK) employing the KiNativ® platform [34] (ActivX 
Biosciences Inc., La Jolla, CA). KiNativ® is a robust, 
high performance mass spectrometry (LC-MS2) assay that 
uses biotinylated probes to measure relevant changes in 
the affinity to the ATP-binding sites of 205 native kinases 
as a function of cellular context [34]. We also validated 
SAB298 effect on the activity of SRC-family kinases by 
probing for phosphorylated Y416, the marker of activated 
SFKs, with anti-IEDNEpYTAR antibodies (also known as 
Y419, #2101, Cell Signaling Technology, Beverly, MA). 
In some cases the cells were incubated overnight with 20 
µM proteasome inhibitor MG-132 (CAS 133407-82-6, 
Millipore Sigma, Burlington, MA) to rescue degradation.
SFKs-knockdown with short hairpin RNA 
(shRNA)
We used puromycin-bearing lentiviral vectors 
pLKO.1 shRNA targeted to SRC, YES, LYN and FYN to 
test the effects of downregulation of specific kinases on 
cell proliferation and signal transduction, employing empty 
vector SHC001 as a negative control (MISSION, Sigma-
Aldrich, Supplementary Table 4). The plasmids were 
packaged in lentiviral vectors with ViraPower™ Lentiviral 
Packaging Mix kit (Thermo Fisher, cat #K497500), or 
with two packaging vectors psPAX2 and pMD2G, and 
transfected into 293T cells. The medium was collected 
and filtered with Millex-GV 33 mm PVDF filter (Millipore 
Figure 7: SAB298 and UM-164 inhibit SFK activity but have opposite effects on ERK and p38. (A) Western blot showing 
common inhibition of SFK (pSFK Y416) in YUSIV, 501 mel and YUROB melanoma cells in response to the two inhibitors, but pERK was 
inhibited only in response to UM-164 (pERK T202/Y204). (B) stimulation of pp38 T180/Y182 in YUSIV melanoma cells incubated for 
increasing periods of time with SAB298. (C) Trametinib, but not SAB298, inhibits pp38 T180/Y182.
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SLGV033RS) and then concentrated with Amicon Ultra-15 
centrifugal filters (Millipore UFC910024). Melanoma 
cells were infected with the lentiviruses, selected with 
puromycin for two days, and three days later collected and 
processed for western blotting. In addition, the knockdown 
cells were seeded in 96-well plates and tested for cell 
proliferation in the absence and presence of puromycin 
with the CellTiter-Glo® Luminescent Cell Viability Assay, 
as described above.
Western blotting and antibodies 
We used standard techniques to identify changes in 
intracellular signaling in response to various treatments 
[32]. Briefly, melanoma cells were incubated with test 
compounds, using DMSO as a control, collected by 
scraping on ice, and lysed in RIPA buffer supplemented 
with protease and phosphatase inhibitors (MA #78428, 
and #78425, respectively, Thermo Fisher Scientific, 
Waltham, MA). Protein concentrations were measured 
with the BioRad kit (Bio-Rad Laboratories, Hercules, 
CA), SDS sample buffer was added, extracts were heated 
at 95° C, sonicated and centrifuged. Cell extracts (20 µg/
lane) were fractionated in 3%–8% or 4–12 % tris-acetate 
gel (NP0006, NuPAGE Life Technologies) [32]. We 
probed with the following primary antibodies: phospho-
SRC Tyr416 (CST #2101S), pSRC Tyr527 (#2105), 
SRC (#2108), pPI3K p85 Y458/p55 Y199 (#4228), 
LYN (C13F9, #2796), FYN (#4023), phospho-MEK1/2 
pSer217/221 (#9121), MEK1/2, phospho-ERK2 pThr202/
Figure 8: SAB298 inactivates PP2A, SHP2 via ERBB2 inhibition. (A) SAB298 increases the levels of inactivated PP2A (pPP2A 
Y307) in YUSIK and YUSIV melanoma cells in a fashion similar to okadaic acid (Okadaic a). Active (unphosphorylated) PP2A is not 
dependent on the presence of pY416 SFK. Panels B and C show SHP2 inactivation by SAB298 in YUSIK, YUROB and YUSOC, but not 
YUGASP melanoma cells (pSHP2 Y542). Suppression of SHP2 is associated with SAB298 induced inactivation of ERBB2 (pERBB2 
Y1196) (C, D).
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Figure 9: Suppression of MITF in response to SAB298.  (A) MITF levels in melanoma cells incubated for increasing periods of 
times with SAB298 (0.5 µM). The oncogenic status of each cell line is indicated on the top and the IC50 on the bottom of the panels. (B) 
The MEK inhibitor SCH772984 (0.5 µM) abolished SAB298 (0.5 µM) induced suppression of MITF. Cells were harvested after 6 hrs 
treatment with the drugs. (C) The proteasomal inhibitor MG-132 (20 µM, 24 hrs) suppressed MITF degradation in response to SAB298. 
(D) The SRC inhibitor UM-164 (1 µM, 6 hrs) increases MITF expression. (E) Tyrosinase levels decrease in response to SAB298 (0.5 µM 
for 20 hrs) due to downregulation of MITF. 
Figure 10: Schematic representation of intracellular signaling induced by SAB298 and UM-164. The figure shows SAB298 
and UM-164 common inhibition of SFK and PI3K activities (┴) that lead to growth arrest but opposite effects on MITF (down- versus up-
regulation) that may contribute to long term response to the drug, such as development of resistance in the presence of high levels of MITF.
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Tyr204 (#9101), ERK1/2 (#9107), phospho-p38 kinase 
T180/Y182 (#9216), p38 kinase (#9212), PP2A (#2259), 
pSHP2 Y542 (#3751), SHP2 (D50F2, #3397), ERBB2 
(D8F12 XP(R), #4290), phospho-ERBB2 Y1196 (D66B7 
#6942), MYC (D84C12, #5605); GAPDH (14C10, 
#2118), all from Cell Signaling Technology, Beverly, 
MA; phospho-PP2A Y307 (AF3989), and MITF (clone 
D5, #AF5769) from R&D Systems, Inc., Minneapolis, 
MN; p27KIP1 (#10241) and YES (#610375) from BD 
Biosciences, San Jose, CA; Cyclin D1 (#04-221) and 
β-actin (mouse mAb A5316) from MilliporeSigma, St. 
Louis, MO; PI3K Antibody (p85 alpha, NSJ R30480) 
from Bioreagents, 9921 Carmel Mountain Rd #352, San 
Diego, CA. All antibodies were used at the concentrations 
recommended by the manufacturers.
In vivo mouse studies
All procedures involving animals were approved by 
the Institutional Animal Care and Use Committee of Yale 
University. YUSIK melanoma cells were grown to 80% 
confluency in 150 cm2 flasks, detached by trypsinization, 
washed with PBS, and cell pellets were resuspended in 
1:1 mixture of PBS and matrigel (BD Bioscience Cat 
#354234) to sustain cell viability. The cells (4 × 106/100 
µl) were injected subcutaneously in the back flank of 
six weeks old female athymic Nude-Foxn1nu (nu/nu) 
mice (Charles River Laboratories, Wilmington, MA), 
and tumors were measuring daily with a caliper (length, 
width, and depth). When tumors reached palpable size 
(between 25–40 mm3), the animals were randomized by 
tumor size and body weigh into two groups and were daily 
injected intraperitoneally with SAB298 (batch #AU0588-
91, Sabila Biosciences LLC, 5 Overlook Road, New City, 
New York, 10956) or vehicle as controls (N = 6/each). The 
injections contained SAB298 (0.5% W/V) in a solution of 
PBS (30%), DMSO (5%), DMA (5%), PEG400 (20%), 
and PG (40%) to assure solubility. The vehicle contained 
the same reagents but without SAB298. 
The tumors size and body weight were measured 
daily and the mice were checked for clinical signs of 
toxicity, such as lethargy, neurological symptoms, diarrhea, 
discharges, morbidity, piloerection and weight loss 
(>20%). None of them or any other abnormal indication 
were observed.
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